HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM.
Biondini M, et al. Among authors: el houjeiri l.
Oncogene. 2022 Mar;41(12):1701-1717. doi: 10.1038/s41388-022-02206-z. Epub 2022 Feb 2.
Oncogene. 2022.
PMID: 35110681